JP2021534165A5 - - Google Patents

Info

Publication number
JP2021534165A5
JP2021534165A5 JP2021507775A JP2021507775A JP2021534165A5 JP 2021534165 A5 JP2021534165 A5 JP 2021534165A5 JP 2021507775 A JP2021507775 A JP 2021507775A JP 2021507775 A JP2021507775 A JP 2021507775A JP 2021534165 A5 JP2021534165 A5 JP 2021534165A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
months
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046467 external-priority patent/WO2020037024A1/en
Publication of JP2021534165A publication Critical patent/JP2021534165A/ja
Publication of JP2021534165A5 publication Critical patent/JP2021534165A5/ja
Pending legal-status Critical Current

Links

JP2021507775A 2018-08-16 2019-08-14 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 Pending JP2021534165A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765093P 2018-08-16 2018-08-16
US62/765,093 2018-08-16
PCT/US2019/046467 WO2020037024A1 (en) 2018-08-16 2019-08-14 Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2021534165A JP2021534165A (ja) 2021-12-09
JP2021534165A5 true JP2021534165A5 (https=) 2022-08-12

Family

ID=69525825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507775A Pending JP2021534165A (ja) 2018-08-16 2019-08-14 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用

Country Status (13)

Country Link
US (1) US20210308208A1 (https=)
EP (1) EP3836950A4 (https=)
JP (1) JP2021534165A (https=)
KR (1) KR20210046016A (https=)
CN (1) CN112584872A (https=)
AU (1) AU2019321442A1 (https=)
BR (1) BR112021001691A2 (https=)
CA (1) CA3109116A1 (https=)
EA (1) EA202190102A1 (https=)
IL (1) IL280617A (https=)
MX (1) MX2021001058A (https=)
SG (1) SG11202101428UA (https=)
WO (1) WO2020037024A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN115348971A (zh) * 2020-03-30 2022-11-15 国立研究开发法人国立癌症研究中心 抗体-药物缀合物
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
WO2021245238A1 (en) 2020-06-04 2021-12-09 Bioinvent International Ab Improving antibody tolerability associated with intravenous administration
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
SI3071237T1 (sl) * 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
SG11201609372UA (en) * 2014-05-22 2016-12-29 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
PT3347054T (pt) * 2015-09-11 2021-07-15 Genmab As Regimes de dosagem para conjugados fármaco-anticorpo anti-tf
EA202090741A1 (ru) * 2017-11-02 2020-07-30 Генмаб А/С Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.

Similar Documents

Publication Publication Date Title
JP2021534165A5 (https=)
JP2021518394A5 (https=)
CN113924318B (zh) 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法
JP2022513386A5 (https=)
JP2021523158A5 (https=)
JP2021523233A5 (https=)
JP2021515017A5 (https=)
JP2021501776A5 (https=)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2023500888A5 (https=)
JP2023500697A5 (https=)
IL278400B2 (en) Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
JP2012522513A5 (https=)
TW201900221A (zh) 抗folr1免疫偶聯物與抗pd-1抗體之組合
JP2015500822A5 (https=)
JP2022541591A5 (https=)
JP2025501978A5 (https=)
JP2023508496A5 (https=)
JP2022544227A5 (https=)
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2025015588A (ja) 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
JP2023542879A5 (https=)
JP2023545432A5 (https=)
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2024536383A5 (https=)